Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2013-05-29

Clinical Trial Update: A Safety and Efficacy Study of Canagliflozin in Older Patients (55 to 80 Years of Age) With Type 2 Diabetes Mellitus [Phase 3]

View source ↗

Summary

Phase 3 safety and efficacy data for canagliflozin in older adults (55-80) with Type 2 diabetes have been completed. Results were posted in 2013.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • INVOKANA (CANAGLIFLOZIN)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Diabetes Mellitus, Type 2 | Phase 3 | Status: COMPLETED | Results posted: 2013-05-29